Amgen | AMGN


EPS Reference Time Actual Consensus Previous
2026-11-03 FY2026Q3 PM 5.76 5.64
2026-08-04 FY2026Q2 PM 5.59 6.02
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58



Peers Price Chg Day Year Date
Takeda 5,694.00 -153.00 -2.62% 35.57% Jul/30
AbbVie 263.62 0.42 0.16% 39.25% Jul/29
Agios Pharmaceuticals 35.05 -0.94 -2.61% -6.63% Jul/29
ALKERMES 48.33 -2.17 -4.30% 79.00% Jul/29
Amgen 387.64 -5.46 -1.39% 28.63% Jul/29
Biogen 209.42 3.81 1.85% 65.37% Jul/29
BioMarin Pharmaceutical 61.37 -0.70 -1.13% 4.35% Jul/29
Bristol-Myers Squibb 63.11 -0.49 -0.77% 37.26% Jul/29
Coherus Biosciences 1.41 -0.03 -2.08% 45.36% Jul/29
Exelixis 55.35 -1.16 -2.05% 50.18% Jul/29

Indexes Price Day Year Date
US500 7338 -112.64 -1.52% 15.75% Jul/30
USND 24443 -433.97 -1.74% 15.68% Jul/29
US30 51645 -1,153.18 -2.19% 17.03% Jul/30
US100 27337 -570.82 -2.06% 17.74% Jul/30

Amgen traded at $387.64 this Wednesday July 29th, decreasing $5.46 or 1.39 percent since the previous trading session. Looking back, over the last four weeks, Amgen lost 7.05 percent. Over the last 12 months, its price rose by 28.63 percent. Looking ahead, we forecast Amgen to be priced at 368.11 by the end of this quarter and at 345.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Stock Price Hits 11-week High
Amgen shares increased to 358.73 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.78%, and in the last 12 months, it increased 28.52%.
2026-06-25
Amgen Stock Price Hits 5-week High
Amgen shares increased to 345.87 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.8%, and in the last 12 months, it increased 20.51%.
2026-06-04
Amgen Stock Price Hits 14-week Low
Amgen shares decreased to 334.00 USD, the lowest since January 2026. Over the past 4 weeks, Amgen lost 3.77%, and in the last 12 months, it increased 16.38%.
2026-04-29